Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Induction of centrosome amplification and chromosome instability in p53-null cells by transient exposure to subtoxic levels of S-phase-targeting anticancer drugs

Abstract

Chromosome instability (CIN) is one of the most important phenotypes in tumor progression, introducing multiple mutations required for acquisition of further malignant characteristics. Abnormal amplification of centrosomes, which is frequently observed in human cancer, has been shown to contribute to CIN by increasing the frequency of mitotic defects. Here, we show that transient exposure to subtoxic concentrations of commonly used anticancer drugs that target DNA synthesis induces centrosome amplification in cells lacking p53 tumor suppressor protein, by allowing continuous centrosome duplication in the absence of DNA synthesis. When these cells are released from cell cycle arrest by removal of drugs, cells suffer extensive destabilization of chromosomes. Considering that p53 is the most frequently mutated gene in human cancer and that CIN is known to be associated with acquisition of malignant phenotypes, our observations may explain why recurrent tumors, after chemotherapy, often exhibit more malignant characteristics than the original tumors. The tumor cells that are exposed to subtoxic levels of DNA synthesis-targeting drugs will be arrested and undergo centrosome amplification. Upon cessation of chemotherapy, these cells will re-enter cell cycling, and experience extensive CIN due to the presence of amplified centrosomes. This in turn promotes generation of tumor cells equipped with further malignant characteristics.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Balczon R, Bao L, Zimmer WE, Brown K, Zinkowski RP and Brinkley BR . (1995). J. Cell Biol., 130, 105–115.

  • Brinkley BR and Goepfert TM . (1998). Cell Motil. Cytoskeleton, 41, 281–288.

  • Carroll PE, Okuda M, Horn HF, Biddinger P, Stambrook PJ, Gleich LL, Li Y-Q, Tarapore P and Fukasawa K . (1999). Oncogene, 18, 1935–1944.

  • Chen S, Blanck G and Pollack RE . (1983). Proc. Natl. Acad. Sci. USA, 80, 5670–5674.

  • Cheng KC and Loeb LA . (1993). Adv. Cancer Res., 60, 121–156.

  • Chiba S, Okuda M, Mussman JG and Fukasawa K . (2000). Exp. Cell Res., 258, 310–321.

  • D'Assoro AB, Lingle WL and Salisbury JL . (2002). Oncogene, 21, 6146–6153.

  • Doxsey S . (2001). Nat. Rev. Mol. Cell. Biol., 2, 688–698.

  • El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B . (1993). Cell, 75, 817–825.

  • Fukasawa K . (2002). Oncogene, 21, 6140–6145.

  • Fukasawa K, Choi T, Kuriyama R, Rulong S and Vande Woude GF . (1996). Science, 271, 1744–1747.

  • Gu Y, Turck CW and Morgan DO . (1993). Nature, 366, 707–710.

  • Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ . (1993). Cell, 75, 805–816.

  • Harris CC . (1996). J. Natl. Cancer Inst., 88, 1442–1455.

  • Hinchcliffe EH, Li C, Thompson EA, Maller JL and Sluder G . (1999). Science, 283, 851–854.

  • Hollstein M, Sidransky D, Vogelstein B and Harris CC . (1991). Science, 253, 49–53.

  • Izumi H, Hara T, Oga A, Matsuda K, Sato Y, Naito K and Sasaki K . (2002). Neoplasia, 4, 103–111.

  • Lacey KR, Jackson PK and Stearns T . (1999). Proc. Natl. Acad. Sci. USA, 96, 2817–2822.

  • Lange BM and Gull K . (1996). Trends Cell Biol., 6, 348–352.

  • Levine AJ, Momand J and Finlay CA . (1991). Nature, 351, 453–456.

  • Mazia D . (1987). Int. Rev. Cytol., 100, 49–92.

  • Meraldi P, Honda R and Nigg EA . (2002). EMBO J., 21, 483–492.

  • Nayak BK and Das GM . (2002). Oncogene, 21, 7226–7229.

  • Oakley BR . (1996). Trends Cell Biol., 2, 1–5.

  • Stearns T, Evans L and Kirschner M . (1991). Cell, 65, 825–836.

  • Tarapore P and Fukasawa K . (2002). Oncogene, 21, 6234–6240.

  • Tarapore P, Horn HF, Tokuyama Y and Fukasawa K . (2001). Oncogene, 20, 3173–3184.

  • Vandre DD and Borisy GG . (1989). Mitosis: Molecules and Mechanisms Hyams JS and Brinkley BR (eds). Academic press, San Diego, 39–75.

    Google Scholar 

  • Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D . (1993). Nature, 366, 701–704.

Download references

Acknowledgements

We thank E Hunter and K George for their technical assistance. This research sponsored by National Institute of Health (CA90522) and National Cancer Institute Training Grant (RB).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kenji Fukasawa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bennett, R., Izumi, H. & Fukasawa, K. Induction of centrosome amplification and chromosome instability in p53-null cells by transient exposure to subtoxic levels of S-phase-targeting anticancer drugs. Oncogene 23, 6823–6829 (2004). https://doi.org/10.1038/sj.onc.1207561

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207561

Keywords

This article is cited by

Search

Quick links